Clinical Trial Detail

NCT ID NCT02890758
Title Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors David Wald
Indications

sarcoma

non-Hodgkin lymphoma

myelodysplastic syndrome

acute myeloid leukemia

acute lymphoblastic leukemia

multiple myeloma

chronic myeloid leukemia

rectum cancer

Ewing sarcoma

rhabdomyosarcoma

chronic lymphocytic leukemia

colon carcinoma

myeloproliferative neoplasm

Hodgkin's lymphoma

Therapies

ALT-803

Age Groups: senior adult

No variant requirements are available.